{"id":4220,"date":"2021-11-18T00:12:24","date_gmt":"2021-11-18T00:12:24","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=4220"},"modified":"2023-08-29T17:52:00","modified_gmt":"2023-08-29T17:52:00","slug":"amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=4220","title":{"rendered":"Amplia Therapeutics\u8bc1\u5b9e\u6297\u764c\u836f\u7269AMP945\u53ef\u4ee5\u6291\u5236\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u5c40\u7076\u9ecf\u7740\u6fc0\u9176"},"content":{"rendered":"

\u6fb3\u5927\u5229\u4e9a\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u6700\u8fd1\u83b7\u5f97\u4e86\u4e00\u9879\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u65b0\u6570\u636e\uff0c\u8be5\u8bd5\u9a8c\u8bc1\u660e\u4e86\u5148\u5bfc\u836f\u7269AMP945\u4f5c\u4e3a\u53e3\u670d\u80f6\u56ca\u5728\u5065\u5eb7\u4eba\u4f53\u5fd7\u613f\u8005\u4e2d\u6291\u5236\u5c40\u7c98\u8fde\u6fc0\u9176(FAK)\u7684\u80fd\u529b\u3002<\/p>\n

\u8be5\u8bd5\u9a8c\u5728\u58a8\u5c14\u672cNucleus Network\u8fdb\u884c\uff0c\u65e8\u5728\u901a\u8fc7\u8bc4\u4f30\u4e0d\u826f\u4e8b\u4ef6\u7684\u6027\u8d28\u3001\u53d1\u751f\u7387\u548c\u4e25\u91cd\u7a0b\u5ea6\u3001\u6212\u65ad\u3001\u4f53\u68c0\u3001\u751f\u547d\u4f53\u5f81\uff0c\u5efa\u7acbAMP945\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u836f\u52a8\u5b66\u3002\u5fc3\u7535\u56fe(ECGs)\u548c\u5b9e\u9a8c\u5ba4\u6d4b\u8bd5\u7ed3\u679c\uff0c\u5305\u62ec\u751f\u5316\u548c\u8840\u6db2\u6807\u8bb0\u7684\u8bc4\u4f30\u3002<\/p>\n

\u6536\u96c6\u4e8656\u540d\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u76ae\u80a4\u6d3b\u68c0\uff0c\u8fd9\u4e9b\u5fd7\u613f\u8005\u5206\u522b\u670d\u7528\u4e86\u5355\u5242\u91cf\u6216\u591a\u5242\u91cf\u7684AMP945(\u5206\u522b\u9ad8\u8fbe125\u6beb\u514b\u548c100\u6beb\u514b)\u6216\u5b89\u6170\u5242\uff0c\u4ee5\u8bc4\u4f30\u836f\u7269\u6291\u5236\u4eba\u4f53\u7ec4\u7ec7\u4e2dFAK\u7684\u80fd\u529b\u3002<\/p>\n

\u4e3a\u7814\u7a76\u98df\u7269\u5bf9\u836f\u7269\u5438\u6536\u7684\u5f71\u54cd\uff0c\u4e00\u7ec4\u53d7\u8bd5\u8005\u5728\u8fdb\u98df\u524d\u540e\u5206\u522b\u7ed9\u4e88AMP945\u3002<\/p>\n

\u654f\u611f\u8bd5\u9a8c<\/h2>\n

\u6837\u54c1\u7684\u5206\u6790\u9700\u8981Amplia\u5f00\u53d1\u4e00\u79cd\u654f\u611f\u7684\u5206\u6790\u65b9\u6cd5\uff0c\u8be5\u65b9\u6cd5\u53ef\u4ee5\u5728\u7ed9\u836f\u524d\u540e\u6d4b\u91cf\u76ae\u80a4\u6837\u54c1\u4e2d\u7684\u6d3b\u6027\u5f62\u5f0fFAK(\u78f7\u9178FAK\u6216pFAK)\u3002<\/p>\n

\u7ed3\u679c\u8868\u660e\uff0c\u53e3\u670dAMP945\u53ef\u5bfc\u81f4\u6d3b\u6027pFAK\u7684\u964d\u4f4e\uff0c\u5e76\u4e14FAK\u6291\u5236\u7684\u7a0b\u5ea6\u4e0e\u836f\u7269\u6c34\u5e73\u76f8\u5173\u3002<\/p>\n

\u8fd9\u4e9b\u6570\u636e\u5c06\u7528\u4e8e\u8fdb\u4e00\u6b65\u5b8c\u5584AMP945\u7684\u5242\u91cf\u6c34\u5e73\uff0c\u7528\u4e8e\u80f0\u817a\u764c\u60a3\u8005\u76842\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/p>\n

\u5b83\u8fd8\u5c06\u4e3a\u8ba1\u5212\u4e8e2022\u5e74\u672b\u5bf9AMP945\u8fdb\u884c\u80ba\u7ea4\u7ef4\u5316\u7684\u8c03\u67e5\u63d0\u4f9b\u6307\u5bfc\u3002<\/p>\n

\u4e0b\u4e00\u9636\u6bb5\u7684\u8bd5\u9a8c<\/h2>\n

Amplia\u9996\u5e2d\u79d1\u5b66\u5b98Dr Mark Devlin\u5f88\u9ad8\u5174\u7b2c\u4e00\u9636\u6bb5\u7684\u6570\u636e\u53ef\u4ee5\u652f\u6301\u4e0b\u4e00\u9636\u6bb5\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5e76\u8868\u793a\u65b0\u7684\u68c0\u6d4b\u65b9\u6cd5\u5df2\u7ecf\u88ab\u8bc1\u5b9e\u662f\u6307\u5bfc\u5242\u91cf\u9009\u62e9\u7684\u4e00\u79cd\u6d4b\u8bd5\u65b9\u6cd5\u3002<\/p>\n

\u4ed6\u8bf4:\u201c\u6211\u4eec\u5728\u52a8\u7269\u6a21\u578b\u4e2d\u89c2\u5bdf\u5230AMP945\u5bf9FAK\u7684\u6291\u5236\u4f5c\u7528\uff0c\u8fd9\u4e0e\u6297\u80bf\u7624\u548c\u6297\u7ea4\u7ef4\u5316\u6d3b\u6027\u6709\u5173\u2026\u2026\u80fd\u591f\u5728\u4eba\u7c7b\u5fd7\u613f\u8005\u4e2d\u89c2\u5bdf\u5230(\u76f8\u540c\u7684\u53cd\u5e94)\u662f\u62fc\u56fe\u7684\u91cd\u8981\u90e8\u5206\u3002\u201d<\/p>\n

\u201c\u5728\u6211\u4eec\u7684\u7b2c\u4e00\u9636\u6bb5\u8bd5\u9a8c\u4e2d\u83b7\u5f97\u5982\u6b64\u6e05\u6670\u548c\u5f15\u4eba\u6ce8\u76ee\u7684FAK\u6291\u5236\u6570\u636e\u662f\u975e\u5e38\u4ee4\u4eba\u9ad8\u5174\u7684\uff0c\u5e76\u4e14\u4e3a\u6211\u4eec\u5f00\u59cb\u5728\u60a3\u8005\u4e2d\u8bd5\u9a8cAMP945\u63d0\u4f9b\u4e86\u989d\u5916\u7684\u5b89\u6170\u3002\u201d<\/p>\n

Dr Devlin\u8bf4\uff0c\u5bf9\u7b2c\u4e00\u9636\u6bb5\u8bd5\u9a8c\u7684\u4e3b\u8981\u3001\u6b21\u8981\u548c\u63a2\u7d22\u6027\u7ec8\u70b9\u7684\u5ba1\u67e5\u8bc1\u5b9e\uff0c\u8be5\u836f\u7269\u5728\u6240\u6709\u6d4b\u8bd5\u5242\u91cf\u4e0b\u90fd\u662f\u5b89\u5168\u4e14\u8010\u53d7\u6027\u826f\u597d\u7684\u3002<\/p>\n

\u5b83\u8fd8\u5c55\u793a\u4e86\u201c\u4f18\u5f02\u7684\u836f\u4ee3\u52a8\u529b\u5b66\u7279\u6027\u201d\uff0c\u4f7f\u5176\u9002\u5408\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u7ed9\u836f\uff0c\u5e76\u80fd\u591f\u4e0e\u9884\u671f\u7684FAK\u9776\u70b9\u7ed3\u5408\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"

\u6fb3\u5927\u5229\u4e9a\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u6700\u8fd1\u83b7\u5f97\u4e86\u4e00\u9879\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u65b0\u6570\u636e\uff0c\u8be5\u8bd5\u9a8c\u8bc1\u660e\u4e86\u5148\u5bfc\u836f\u7269AMP945\u4f5c\u4e3a\u53e3\u670d\u80f6\u56ca\u5728\u5065\u5eb7\u4eba\u4f53\u5fd7\u613f\u8005\u4e2d\u6291\u5236\u5c40\u7c98\u8fde\u6fc0\u9176(FAK)\u7684\u80fd\u529b\u3002 \u8be5\u8bd5\u9a8c\u5728\u58a8\u5c14\u672cNucleus Network\u8fdb\u884c\uff0c\u65e8\u5728\u901a\u8fc7\u8bc4\u4f30\u4e0d\u826f\u4e8b\u4ef6\u7684\u6027\u8d28\u3001\u53d1\u751f\u7387\u548c\u4e25\u91cd\u7a0b\u5ea6\u3001\u6212\u65ad\u3001\u4f53\u68c0\u3001\u751f\u547d\u4f53\u5f81\uff0c\u5efa\u7acbAMP945\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u836f\u52a8\u5b66\u3002\u5fc3\u7535\u56fe(ECGs)\u548c\u5b9e\u9a8c\u5ba4\u6d4b\u8bd5\u7ed3\u679c\uff0c\u5305\u62ec\u751f\u5316\u548c\u8840\u6db2\u6807\u8bb0\u7684\u8bc4\u4f30\u3002 \u6536\u96c6\u4e8656\u540d\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u76ae\u80a4\u6d3b\u68c0\uff0c\u8fd9\u4e9b\u5fd7\u613f\u8005\u5206\u522b\u670d\u7528\u4e86\u5355\u5242\u91cf\u6216\u591a\u5242\u91cf\u7684AMP945(\u5206\u522b\u9ad8\u8fbe125\u6beb\u514b\u548c100\u6beb\u514b)\u6216\u5b89\u6170\u5242\uff0c\u4ee5\u8bc4\u4f30\u836f\u7269\u6291\u5236\u4eba\u4f53\u7ec4\u7ec7\u4e2dFAK\u7684\u80fd\u529b\u3002 \u4e3a\u7814\u7a76\u98df\u7269\u5bf9\u836f\u7269\u5438\u6536\u7684\u5f71\u54cd\uff0c\u4e00\u7ec4\u53d7\u8bd5\u8005\u5728\u8fdb\u98df\u524d\u540e\u5206\u522b\u7ed9\u4e88AMP945\u3002 \u654f\u611f\u8bd5\u9a8c \u6837\u54c1\u7684\u5206\u6790\u9700\u8981Amplia\u5f00\u53d1\u4e00\u79cd\u654f\u611f\u7684\u5206\u6790\u65b9\u6cd5\uff0c\u8be5\u65b9\u6cd5\u53ef\u4ee5\u5728\u7ed9\u836f\u524d\u540e\u6d4b\u91cf\u76ae\u80a4\u6837\u54c1\u4e2d\u7684\u6d3b\u6027\u5f62\u5f0fFAK(\u78f7\u9178FAK\u6216pFAK)\u3002 \u7ed3\u679c\u8868\u660e\uff0c\u53e3\u670dAMP945\u53ef\u5bfc\u81f4\u6d3b\u6027pFAK\u7684\u964d\u4f4e\uff0c\u5e76\u4e14FAK\u6291\u5236\u7684\u7a0b\u5ea6\u4e0e\u836f\u7269\u6c34\u5e73\u76f8\u5173\u3002 \u8fd9\u4e9b\u6570\u636e\u5c06\u7528\u4e8e\u8fdb\u4e00\u6b65\u5b8c\u5584AMP945\u7684\u5242\u91cf\u6c34\u5e73\uff0c\u7528\u4e8e\u80f0\u817a\u764c\u60a3\u8005\u76842\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002 \u5b83\u8fd8\u5c06\u4e3a\u8ba1\u5212\u4e8e2022\u5e74\u672b\u5bf9AMP945\u8fdb\u884c\u80ba\u7ea4\u7ef4\u5316\u7684\u8c03\u67e5\u63d0\u4f9b\u6307\u5bfc\u3002 \u4e0b\u4e00\u9636\u6bb5\u7684\u8bd5\u9a8c Amplia\u9996\u5e2d\u79d1\u5b66\u5b98Dr Mark Devlin\u5f88\u9ad8\u5174\u7b2c\u4e00\u9636\u6bb5\u7684\u6570\u636e\u53ef\u4ee5\u652f\u6301\u4e0b\u4e00\u9636\u6bb5\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5e76\u8868\u793a\u65b0\u7684\u68c0\u6d4b\u65b9\u6cd5\u5df2\u7ecf\u88ab\u8bc1\u5b9e\u662f\u6307\u5bfc\u5242\u91cf\u9009\u62e9\u7684\u4e00\u79cd\u6d4b\u8bd5\u65b9\u6cd5\u3002 \u4ed6\u8bf4:\u201c\u6211\u4eec\u5728\u52a8\u7269\u6a21\u578b\u4e2d\u89c2\u5bdf\u5230AMP945\u5bf9FAK\u7684\u6291\u5236\u4f5c\u7528\uff0c\u8fd9\u4e0e\u6297\u80bf\u7624\u548c\u6297\u7ea4\u7ef4\u5316\u6d3b\u6027\u6709\u5173\u2026\u2026\u80fd\u591f\u5728\u4eba\u7c7b\u5fd7\u613f\u8005\u4e2d\u89c2\u5bdf\u5230(\u76f8\u540c\u7684\u53cd\u5e94)\u662f\u62fc\u56fe\u7684\u91cd\u8981\u90e8\u5206\u3002\u201d \u201c\u5728\u6211\u4eec\u7684\u7b2c\u4e00\u9636\u6bb5\u8bd5\u9a8c\u4e2d\u83b7\u5f97\u5982\u6b64\u6e05\u6670\u548c\u5f15\u4eba\u6ce8\u76ee\u7684FAK\u6291\u5236\u6570\u636e\u662f\u975e\u5e38\u4ee4\u4eba\u9ad8\u5174\u7684\uff0c\u5e76\u4e14\u4e3a\u6211\u4eec\u5f00\u59cb\u5728\u60a3\u8005\u4e2d\u8bd5\u9a8cAMP945\u63d0\u4f9b\u4e86\u989d\u5916\u7684\u5b89\u6170\u3002\u201d Dr Devlin\u8bf4\uff0c\u5bf9\u7b2c\u4e00\u9636\u6bb5\u8bd5\u9a8c\u7684\u4e3b\u8981\u3001\u6b21\u8981\u548c\u63a2\u7d22\u6027\u7ec8\u70b9\u7684\u5ba1\u67e5\u8bc1\u5b9e\uff0c\u8be5\u836f\u7269\u5728\u6240\u6709\u6d4b\u8bd5\u5242\u91cf\u4e0b\u90fd\u662f\u5b89\u5168\u4e14\u8010\u53d7\u6027\u826f\u597d\u7684\u3002 \u5b83\u8fd8\u5c55\u793a\u4e86\u201c\u4f18\u5f02\u7684\u836f\u4ee3\u52a8\u529b\u5b66\u7279\u6027\u201d\uff0c\u4f7f\u5176\u9002\u5408\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u7ed9\u836f\uff0c\u5e76\u80fd\u591f\u4e0e\u9884\u671f\u7684FAK\u9776\u70b9\u7ed3\u5408\u3002<\/p>\n","protected":false},"author":4,"featured_media":13932,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[58],"yoast_head":"\nAmplia Therapeutics\u8bc1\u5b9e\u6297\u764c\u836f\u7269AMP945\u53ef\u4ee5\u6291\u5236\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u5c40\u7076\u9ecf\u7740\u6fc0\u9176<\/title>\n<meta name=\"description\" content=\"\u6fb3\u5927\u5229\u4e9a\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u6700\u8fd1\u83b7\u5f97\u4e86\u4e00\u9879\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u65b0\u6570\u636e\uff0c\u8be5\u8bd5\u9a8c\u8bc1\u660e\u4e86\u5148\u5bfc\u836f\u7269AMP945\u4f5c\u4e3a\u53e3\u670d\u80f6\u56ca\u5728\u5065\u5eb7\u4eba\u4f53\u5fd7\u613f\u8005\u4e2d\u6291\u5236\u5c40\u7c98\u8fde\u6fc0\u9176(FAK)\u7684\u80fd\u529b\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amplia Therapeutics\u8bc1\u5b9e\u6297\u764c\u836f\u7269AMP945\u53ef\u4ee5\u6291\u5236\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u5c40\u7076\u9ecf\u7740\u6fc0\u9176\" \/>\n<meta property=\"og:description\" content=\"\u6fb3\u5927\u5229\u4e9a\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u6700\u8fd1\u83b7\u5f97\u4e86\u4e00\u9879\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u65b0\u6570\u636e\uff0c\u8be5\u8bd5\u9a8c\u8bc1\u660e\u4e86\u5148\u5bfc\u836f\u7269AMP945\u4f5c\u4e3a\u53e3\u670d\u80f6\u56ca\u5728\u5065\u5eb7\u4eba\u4f53\u5fd7\u613f\u8005\u4e2d\u6291\u5236\u5c40\u7c98\u8fde\u6fc0\u9176(FAK)\u7684\u80fd\u529b\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-18T00:12:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:52:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Amplia-Therapeutics-ASX-ATX-FAK-Focal-Adhesion-Kinase-AMP945-clinical-trial-phase-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Imelda Cotton\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Imelda Cotton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase\/\",\"name\":\"Amplia Therapeutics\u8bc1\u5b9e\u6297\u764c\u836f\u7269AMP945\u53ef\u4ee5\u6291\u5236\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u5c40\u7076\u9ecf\u7740\u6fc0\u9176\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2021-11-18T00:12:24+00:00\",\"dateModified\":\"2023-08-29T17:52:00+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\"},\"description\":\"\u6fb3\u5927\u5229\u4e9a\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u6700\u8fd1\u83b7\u5f97\u4e86\u4e00\u9879\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u65b0\u6570\u636e\uff0c\u8be5\u8bd5\u9a8c\u8bc1\u660e\u4e86\u5148\u5bfc\u836f\u7269AMP945\u4f5c\u4e3a\u53e3\u670d\u80f6\u56ca\u5728\u5065\u5eb7\u4eba\u4f53\u5fd7\u613f\u8005\u4e2d\u6291\u5236\u5c40\u7c98\u8fde\u6fc0\u9176(FAK)\u7684\u80fd\u529b\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amplia Therapeutics\u8bc1\u5b9e\u6297\u764c\u836f\u7269AMP945\u53ef\u4ee5\u6291\u5236\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u5c40\u7076\u9ecf\u7740\u6fc0\u9176\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\",\"name\":\"Imelda Cotton\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"caption\":\"Imelda Cotton\"},\"description\":\"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amplia Therapeutics\u8bc1\u5b9e\u6297\u764c\u836f\u7269AMP945\u53ef\u4ee5\u6291\u5236\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u5c40\u7076\u9ecf\u7740\u6fc0\u9176","description":"\u6fb3\u5927\u5229\u4e9a\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u6700\u8fd1\u83b7\u5f97\u4e86\u4e00\u9879\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u65b0\u6570\u636e\uff0c\u8be5\u8bd5\u9a8c\u8bc1\u660e\u4e86\u5148\u5bfc\u836f\u7269AMP945\u4f5c\u4e3a\u53e3\u670d\u80f6\u56ca\u5728\u5065\u5eb7\u4eba\u4f53\u5fd7\u613f\u8005\u4e2d\u6291\u5236\u5c40\u7c98\u8fde\u6fc0\u9176(FAK)\u7684\u80fd\u529b\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Amplia Therapeutics\u8bc1\u5b9e\u6297\u764c\u836f\u7269AMP945\u53ef\u4ee5\u6291\u5236\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u5c40\u7076\u9ecf\u7740\u6fc0\u9176","og_description":"\u6fb3\u5927\u5229\u4e9a\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u6700\u8fd1\u83b7\u5f97\u4e86\u4e00\u9879\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u65b0\u6570\u636e\uff0c\u8be5\u8bd5\u9a8c\u8bc1\u660e\u4e86\u5148\u5bfc\u836f\u7269AMP945\u4f5c\u4e3a\u53e3\u670d\u80f6\u56ca\u5728\u5065\u5eb7\u4eba\u4f53\u5fd7\u613f\u8005\u4e2d\u6291\u5236\u5c40\u7c98\u8fde\u6fc0\u9176(FAK)\u7684\u80fd\u529b\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase\/","og_site_name":"smallcapsCN","article_published_time":"2021-11-18T00:12:24+00:00","article_modified_time":"2023-08-29T17:52:00+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Amplia-Therapeutics-ASX-ATX-FAK-Focal-Adhesion-Kinase-AMP945-clinical-trial-phase-1.jpg","type":"image\/jpeg"}],"author":"Imelda Cotton","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Imelda Cotton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase\/","url":"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase\/","name":"Amplia Therapeutics\u8bc1\u5b9e\u6297\u764c\u836f\u7269AMP945\u53ef\u4ee5\u6291\u5236\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u5c40\u7076\u9ecf\u7740\u6fc0\u9176","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2021-11-18T00:12:24+00:00","dateModified":"2023-08-29T17:52:00+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e"},"description":"\u6fb3\u5927\u5229\u4e9a\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u6700\u8fd1\u83b7\u5f97\u4e86\u4e00\u9879\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u65b0\u6570\u636e\uff0c\u8be5\u8bd5\u9a8c\u8bc1\u660e\u4e86\u5148\u5bfc\u836f\u7269AMP945\u4f5c\u4e3a\u53e3\u670d\u80f6\u56ca\u5728\u5065\u5eb7\u4eba\u4f53\u5fd7\u613f\u8005\u4e2d\u6291\u5236\u5c40\u7c98\u8fde\u6fc0\u9176(FAK)\u7684\u80fd\u529b\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-anti-cancer-drug-amp945-inhibit-focal-adhesion-kinase\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Amplia Therapeutics\u8bc1\u5b9e\u6297\u764c\u836f\u7269AMP945\u53ef\u4ee5\u6291\u5236\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u5c40\u7076\u9ecf\u7740\u6fc0\u9176"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e","name":"Imelda Cotton","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","caption":"Imelda Cotton"},"description":"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.","url":"https:\/\/smallcapscn.x5view.co\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4220"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4220"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4220\/revisions"}],"predecessor-version":[{"id":13931,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4220\/revisions\/13931"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/13932"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}